Funding for this research was provided by:
National Institute for Health Research (ICA-CL-2016-02-014)
Oak Foundation (OCAY-13-309)
Received: 21 October 2019
Accepted: 5 March 2020
First Online: 20 March 2020
Ethics approval and consent to participate
: Not applicable.
: Not applicable.
: W.E. van Spil: none.S.M.A. Bierma-Zeinstra: provides consulting advice for Infirst Healthcare.N.K. Arden: provides consulting advice to Merck, Flexion, Freshfields Bruckhaus, Regeneron and Pfizer/Lilly.A.-C. Bay-Jensen: employee and shareholder at Nordic Bioscience. Partner and WP lead in the IMI-APPROACH consortium.V. Byers Kraus: none.L. Carlesso: none.R. Christensen: none.L.A. Deveza: received partial reimbursement of conference registration cost from Pfizer.M. Van Der Esch: none.P. Kent: none.J. Knoop: none.C. Ladel: employee of Merck KGaA.C.B. Little: conducts research funded by a number pharmaceutical companies through contracts negotiated with and finances controlled by the University of Sydney and/or Northern Sydney Local Health District; provides consulting advice to Galapagos Pharmaceuticas and Merck Serono.R.F. Loeser: provides consulting advice for Unity Biotechnology and is on the Scientific Advisory Board for Reginosine. He has received research funding from Bioventis.E. Losina: provided consulting advice for Regeneron. Receives research funding from Genentech.K. Mills: none.A. Mobasheri: provided consulting advice for Abbvie, Pfizer Consumer Health (PCH), Galapagos and Servier; received funding from the European Commission through the Structural and Social Funds programmes; received investigator initiated grant support from Merck KGaA.A.E. Nelson: provides consulting advice for Glaxo Smith Kline, receives royalties from Health Press, Ltd., provided presentations for MedScape and QuantiaMD.T. Neogi: none.G.M. Peat: none.A.-C. Rat: none.M. Steultjens: none.M.J. Thomas: none.A.M. Valdes: none.D.J. Hunter: provides consulting advice for Merck Serono, Tissuegene, and TLCBio.